NCT00347126|Completed
Results of Mass Switch From Latanoprost to Travoprost
Efficacy and Safety of a Systematic Switch From Latanoprost to Travoprost in Patients With Glaucoma
Loading search results
Efficacy and Safety of a Systematic Switch From Latanoprost to Travoprost in Patients With Glaucoma
Sponsor study identifier
observational
372
1 country
1
Study Start
April 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
April 2008
Actual (reported)Prostaglandin analogs are a leading class of glaucoma drugs with a proven safety and efficacy for controlling IOP. They include latanoprost, bimatoprost, travoprost and unoprostone. Recently, the Singapore National Eye Center (SNEC) awarded a tender for prostaglandin analogues to Alcon, the manufacturer of travoprost. Since then, all subsidized patients previously treated with latanoprost were systematically switched to travoprost and this process will continue for the rest of this year. In this study, we propose to prospectively study the efficacy and safety of switching from latanoprost to travoprost in a large series of glaucoma patients at SNEC. A total of 372 consecutive patients being switched from latanoprost to travoprost will be followed up for 12 weeks following the switch. In addition to intraocular pressure, the safety and tolerability (with particular emphasis on hyperemia) of travoprost will be examined.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2008
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2006
Date type not reportedThis date has not been verified as actual or estimated.
June 30, 2006
Actual (reported)July 4, 2006
Actual (reported)April 2008
Actual (reported)Patients on treatment with latanoprost who are switched to travoprost therapy
Singapore National Eye Centre
Singapore, 168751, Singapore
Tin Aung, FRCS, PhD
Singapore National Eye Centre
First Submitted
June 30, 2006
First Posted
July 4, 2006
Study Start
April 2006
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
April 2008
Actual (reported)IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy
Contact the study team to confirm eligibility.
Last Updated
May 12, 2010
Record last verified: 2010-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: